- Title
- Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
- Creator
- Dowsett, Mitch; Allred, Craig; Bishop, Hugh; Ellis, Ian; Larsimont, Danis; Sasano, Hironobu; Carder, Pauline; Cussac, Antonio L.; Knox, Fiona; Speirs, Valerie; Forbes, John; Buzdar, Aman; Knox, Jill; Quinn, Emma; Salter, Janine; Wale, Chris; Cuzick, Jack; Houghton, Joan; Williams, Norman; Mallon, Elizabeth
- Relation
- Journal of Clinical Oncology Vol. 26, Issue 7, p. 1059-1065
- Publisher Link
- http://dx.doi.org/10.1200/JCO.2007.12.9437
- Publisher
- American Society of Clinical Oncology
- Resource Type
- journal article
- Date
- 2008
- Description
- Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-receptor (PgR) expression and human epidermal growth factor 2 (HER-2) status with time to recurrence (TTR) in postmenopausal women with hormone receptor–positive primary breast cancer treated with anastrozole or tamoxifen as adjuvant therapy. Patients and Methods: Formalin-fixed, paraffin-embedded tumor blocks were retrospectively collected from patients in the monotherapy arms of the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial and centrally tested for ER, PgR and HER-2. ER and PgR were scored using continuous scales and HER-2 was scored as 0 to 3+ with 2+ cases being analyzed by fluorescence in situ hybridization. Results: Blocks were collected from 2,006 of 5,880 eligible patients. Tissue was assessable and ER and/or PgR positivity confirmed centrally in 1,782 cases. In these, TTR was longer for anastrozole than for tamoxifen by a similar extent to that in the overall trial. None of the three biomarkers identified a set of patients with differential benefit from anastrozole over tamoxifen. Patients with low ER, low PgR, and high HER-2 expression had a poorer prognosis with either drug. Only 2.6% of patients in the highest quartile of PgR experienced recurrence after 5 years, compared with 13.2% in the lowest quartile. Conclusion: Quantitative expression of ER and PgR and HER-2 status did not identify patients with differential relative benefit from anastrozole over tamoxifen: TTR was longer for anastrozole than for tamoxifen in all molecular subgroups. Low ER or PgR or high HER-2 expression are associated with a high risk of recurrence with either anastrozole or tamoxifen.
- Subject
- estrogen-receptor; progesterone-receptor; human epidermal growth factor 2 (HER-2); time to recurrence; postmenopausal women; tamoxifen; anastrozole
- Identifier
- uon:5453
- Identifier
- http://hdl.handle.net/1959.13/43333
- Identifier
- ISSN:0732-183X
- Reviewed
- Hits: 40924
- Visitors: 25879
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|